Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Geeta Vemuri
AddedMar 31, 2024
UpdatedMay 31, 2026
Geeta Vemuri

Geeta Vemuri

Co-Founder, Agent Capital

CrunchbaseLinkedIn

Geeta Vemuri's Career

Agent Capital
Agent Capital

Waltham, MA, US

Co-Founder
Cantai Therapeutics
Cantai Therapeutics

Philadelphia, PA, US

Board Member· Board
Immunitas Therapeutics
Immunitas Therapeutics

Waltham, MA, US

Board Member· Board
Gliknik
Gliknik

Baltimore, MD, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Geeta Vemuri's Career

Agent Capital
Agent Capital
Investment FirmInvestment Firm122016Waltham, MA, US
Co-Founder

Leadership at Agent Capital

Preston NoonPreston NoonCo-Founder

Similar to Agent Capital

CareCapitalCareCapitalRhode Island, USest. 2015CareCapitalRhode Island, US · est. 2015

CareCapital: A patient-focused healthcare tech investment group fostering innovative visions.

Investment Firm175
CyberAgent CapitalCyberAgent Capitalward area of Tokyo, Tokyo, JPest. 2006CyberAgent Capitalward area of Tokyo, Tokyo, JP · est. 2006

CyberAgent Capital: A venture capital firm driving global innovation with unicorn startups.

Investment Firm16
GT Healthcare Capital PartnersGT Healthcare Capital PartnersCentral Falls, RI, USest. 2015GT Healthcare Capital PartnersCentral Falls, RI, US · est. 2015

GT Healthcare Capital: A venture capital firm investing in global healthcare innovations for enhanced patient care.

Investment Firm30
HealthTrend CapitalHealthTrend CapitalBoston, MA, USest. 2021HealthTrend CapitalBoston, MA, US · est. 2021

HealthTrend Capital: A venture growth equity firm with a healthcare focus, open to all stages.

Investment Firm2
Cantai Therapeutics
Cantai Therapeutics
Seed$700k62023Philadelphia, PA, US
Board Member· Board
Immunitas Therapeutics
Immunitas Therapeutics
Series B$97M332019Waltham, MA, US
Board Member· Board

Leadership at Immunitas Therapeutics

Laura BrassLaura BrassBoard Member
K. Dane WittrupK. Dane WittrupBoard Member
Mario SuvaMario SuvaCo-Founder
Brian HalakBrian HalakBoard Member
Amanda WagnerAmanda WagnerCEO
Lucio IannoneLucio IannoneBoard Member

Similar to Immunitas Therapeutics

Immune-Onc TherapeuticsImmune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35
ImmunaiImmunaiNew York City, NY, USBiomarkers, Biotechest. 2018ImmunaiNew York City, NY, US · est. 2018

Immunai, a biotech firm, uses single-cell genomics and ML for high-resolution immune profiling and biomarker discovery.

Series B · $295M167
ImmunoGenesisImmunoGenesisHouston, TX, USCancer Therapiesest. 2019ImmunoGenesisHouston, TX, US · est. 2019

ImmunoGenesis: Developing science-based therapies to combat immune-resistant tumors.

Public · $28M38
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
Gliknik
Gliknik
Series C$70.1M752007Baltimore, MD, US
Board Member· Board

Leadership at Gliknik

Paul A. FriedmanPaul A. FriedmanBoard Member
David BlockDavid BlockCEO

Similar to Gliknik

GitrGitrCambridge, MA, USCancer Therapiesest. 2011GitrCambridge, MA, US · est. 2011

GITR Inc: Enhancing immune response with innovative therapies to combat cancer.

Seed · $4.8M6
G1 TherapeuticsG1 TherapeuticsTriangle (historical), NC, USCancer Therapiesest. 2008G1 TherapeuticsTriangle (historical), NC, US · est. 2008

US-based G1 Therapeutics develops innovative treatments for oncology and breast cancer.

Public · $697.4M170
GliacureGliacureBoston, MA, USTherapeuticsest. 2011GliacureBoston, MA, US · est. 2011

Boston-based GliaCure develops innovative therapies for neurological and neuropsychiatric disorders.

Seed · $11.1M8
GlycoMimeticsGlycoMimeticsRockville, MD, USDrugs, Pharmaceuticalsest. 2003GlycoMimeticsRockville, MD, US · est. 2003

US-based GlycoMimetics, Inc. researches, develops, and commercializes specialized drugs for blood cancers and inflammation.

Public · $373.4M39

Geeta Vemuri's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Geeta Vemuri

Geoff BrookeGeoff BrookeCo-Founder · GBS Venture PartnersSatish TadikondaSatish TadikondaBoard Member · Blue Cloud VenturesDavid PerryDavid PerryCo-Founder · NexpriseAdam RensloAdam RensloCo-Founder · Elgia TherapeuticsPaul ManningPaul ManningBoard Member · PBM Capital GroupErkki RuoslahtiErkki RuoslahtiCo-Founder · Lisata Therapeutics